Le Lézard
Classified in: Health, Business
Subject: ERN

Orexo Q4 2021, incl. Full Year Report

UPPSALA, Sweden, Jan. 27, 2022 /PRNewswire/ --

Ready to capitalize on a strong foundation

Q4 2021 highlights

Important events after the period

SEK m, unless otherwise stated





Net revenues





Cost of goods sold





Operating expenses










EBIT margin, %










Earnings per share, before dilution, SEK





Earnings per share, after dilution, SEK





Cash flow from operating activities





Cash and cash equivalents





Unless otherwise stated in this report, all data refers to the Group, and numbers relate to the current quarter while numbers in parentheses relate to the corresponding period in 2020.

Expanding the business

"I am pleased to report that the fourth quarter of  2021 saw a continued strong profit contribution from ZUBSOLV® and sales nearly in line with Q3. The financial contribution from ZUBSOLV® is important to maintain pace and enable us to continue building on the highlights of the quarter. During Q4 we showed a positive outcome for the OX124 pivotal trial, we informed about our new drug delivery platform amorphOXtm, and expanded our pipeline with a new pharmaceutical project OX640 (nasal epinephrine). Additionally, we initiated the launch of MODIAtm and after the end of the period, our partnership with Sober Grid reached a significant milestone establishing an agreement with Walgreens to make our collaborative services available on their Find Care® digital market place during the first quarter."

Full CEO Comments can be read in attached PDF

For further information, please contact
Nikolaj Sørensen, President and CEO, Joseph DeFeo, EVP and CFO, or Lena Wange, IR & Communications Director 
Tel: +46 18 780 88 00, +1 855 982 7658, E-mail: [email protected]

At 2 pm CET, the same day as the announcement of the report, Orexo invites analysts, investors and media to attend a presentation where Nikolaj Sørensen, CEO, Joseph DeFeo, CFO, and Robert Rönn, SVP and Head of R&D, will present the report and host a Q&A. 
Questions can also be sent in advance to [email protected], no later than 11 am CET
Please view the instructions below on how to participate.
Internet: https://tv.streamfabriken.com/orexo-q4-2021
Telephone: SE +46 8 50 55 83 74 UK +44 33 33 00 92 63 US +1 64 67 22 49 02
The presentation material will be available on Orexo´s website prior to the audiocast, view Investors/Reports, presentations.

This information is information that Orexo AB (publ.) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 8.00 am CET on January 27, 2022. 

This information was brought to you by Cision http://news.cision.com


The following files are available for download:


Orexo Q4 2021, incl. Full Year Report_published January 27 2022



These press releases may also interest you

at 08:29
Denver-based healthtech leader Eon announced today the appointment of Kevin Hutchinson and Dan Rieber to the Eon Board of Directors. Mr. Hutchinson and Mr. Rieber join current board members founder and co-CEO, Dr. Aki Alzubaidi, co-CEO Christine...

at 08:26
3 Pillars of Leadership is an executive coaching and consulting firm that helps leaders at all levels of your company. Our clients come from diverse industries such as hospitality, education and gaming to name just a few! We work with senior managers...

at 08:23
As The Hole in the Wall Gang Camp prepares to welcome campers for its 35th summer in Ashford, Conn., CEO James Canton and Board Member Bradley Cooper announced today that the organization will open a second location on the Eastern Shore of Maryland...

at 08:20
Noveome Biotherapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to the company's lead product ST266 for the treatment of...

at 08:20
MedExecWomen, a fast-growing organization dedicated to empowering women in leadership roles in medical device, diagnostics, drug delivery, and digital healthcare, announced today their third annual event will take place on June 14, 2022, in Boston....

at 08:20
Anumana, Inc., an AI-driven health technology company from nference, Inc., today announced that the U.S. Food & Drug Administration (FDA) has granted Breakthrough Device Designation to its AI-enhanced, ECG-based Pulmonary Hypertension (PH) Early...

News published on 27 january 2022 at 02:23 and distributed by: